Verastem is exploding higher following a flurry of positive developments released overnight and early this morning. The primary catalyst is the announcement of robust clinical data for the company's experimental KRAS G12D inhibitor, VS-7375, which demonstrated antitumor activity across multiple cancers, including a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma. This clinical progress is being paired with a strategic $250 million capital raise and the appointment of a new Chief Executive Officer, Michael P. Bailey, to lead the company through its next phase of development.